New Trial Data Sinks Astellas’ Hopes to Expand Indication for Leukemia Drug

Astellas reported new trial data for Xospata that bodes poorly for its chances at an expanded indication as an add-on in the treatment of acute myeloid leukemia (AML), an aggressive blood cancer. The data showed that addition of Xospata after stem cell therapy did not improve relapse-free survival at 2-year followup.

According to Kevin Dunleavy, “AML is an aggressive cancer of the bone marrow and blood. Roughly a third of newly diagnosed AML patients have an alteration of the FLT3 gene. Those with FLT3-ITD mutations have a lower chance to survive and are at a higher risk for getting the disease more than once.”

To read more, click here.

(Source: Fierce Pharma, March 9^th, 2023)